Centre Hospitalier Universitaire d'Angers
Centre Hospitalier Universitaire d'Angers
Angers, France15 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, peripheral arterial disease, peripheral vascular disease, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07223593 | |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-08 | NCT07165028 | |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | Apnea, Body Weight, Dyssomnias, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Signs and Symptoms, Sleep Disorders, Intrinsic, nervous system disorder, nutritional disorder, obesity disorder, obstructive sleep apnea syndrome, overnutrition, respiratory system disorder, sleep apnea syndrome, sleep-wake disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT07225686 | |
| An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 2 | 2026-10-02 | NCT06951217 | |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | Apnea, Body Weight, Dyssomnias, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Signs and Symptoms, Sleep Disorders, Intrinsic, nervous system disorder, nutritional disorder, obesity disorder, obstructive sleep apnea syndrome, overnutrition, respiratory system disorder, sleep apnea syndrome, sleep-wake disorder | Active, not recruiting | Phase 3 | 2026-09-29 | NCT07226765 | |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Granuloma, Hemic and Lymphatic Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, astrocytoma (excluding glioblastoma), connective tissue neoplasm, epithelial neoplasm, glioblastoma, glioma, immune system disorder, immunoproliferative disorder, inflammatory myofibroblastic tumor, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor, sarcoma, solitary fibrous tumor | Recruiting | Phase 1 / Phase 2 | 2026-09-25 | NCT04094610 | |
| A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Body Weight, Body Weight Changes, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Gain, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-09-24 | NCT06439277 | |
| Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease | Nutritional and Metabolic Diseases, inborn mitochondrial metabolism disorder, metabolic disease | Recruiting | Phase 2 | 2026-09-16 | NCT07514338 | |
| Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, central nervous system cancer, epithelial neoplasm, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT07243470 | |
| Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04821622 | |
| Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | Hypersensitivity, Immediate, Nut and Peanut Hypersensitivity, Peanut Hypersensitivity, allergic disease, food allergy, immune system disorder | Active, not recruiting | Phase 3 | 2026-07-22 | NCT07003919 | |
| Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | Muscle Weakness, Neurologic Manifestations, Neuromuscular Manifestations, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 2 | 2026-06-26 | NCT05650229 | |
| Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT | ovarian small cell carcinoma | Recruiting | Phase 2 | 2025-11-28 | NCT04602377 | |
| Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2025-09-24 | NCT06409767 | |
| A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE) | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, disorder of glycogen metabolism, glycogen storage disease II, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, nervous system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2024-11-27 | NCT04093349 |